Results 111 to 120 of about 636,170 (221)

BTK Inhibitor [PDF]

, 2020
WANG XUEHAI, WU CHENGDE, XU YONG, SHEN CHUNLI, LI LI'E, HU GUOPING, YUE YANG, LI JIAN, GUO DILIANG, SHI NENGYANG, HUANG LU, CHEN SHUHUI, TU RONGHUA, YANG ZHONGWEN, ZHANG XUWEN, XIAO QIANG, TIAN HUA, YU YANPING, CHEN HAILIANG, SUN WENJIE, HE ZHENYU, SHEN JIE, YANG JING, TANG JING, ZHOU WEN, YU JING, ZHANG YI, LIU QUAN   +27 more
openaire   +3 more sources

Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025

Experimental Hematology & Oncology
Waldenström macroglobulinemia (WM) is a rare, indolent lymphoplasmacytic lymphoma characterized by bone marrow infiltration of IgM-secreting lymphoplasmacytic cells and associated with the MYD88(L265P) mutation in over 90% of cases.
Yujing Liang, Xinyi Deng, Ziwen Wang, Chuanmiao Xie, Lie Zheng, He Huang, Shaohan Yin, Huageng Huang   +7 more
doaj   +1 more source

''From Molecular Resistance to Tumor Evolution: Insights in BTK Inhibitors, Tumor Microenvironment and Genetic Variants.''

reservedBruton’s tyrosine kinase (BTK) prevails as a key mediator in the elaborate system of immune signaling, with its essential role in maintaining homeostasis of the B lymphocyte compartment.
RUSTEMI, BRISEJDA
core  

Abstract 3232: Development of novel Btk inhibitor, CB988 targering ibrutinib-resistant Btk C481S mutant

, 2017
Introduction: Bruton's tyrosine kinase (Btk) is a member of the Tec family of cytoplasmic tyrosine kinase. Btk plays a crucial role in the BCR signaling, essential for B-cell development, and Btk has been recognized as a validated therapeutic target for ...
Wataru Kawahata, Yasuhiro Iwata, Tokiko Asami, Takao Kiyoi, Masaaki Sawa, Takayuki Irie   +5 more
core   +1 more source

Chemoimmunotherapy‐associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies

HemaSphere, Volume 10, Issue 10, October 2026.
Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe‐Paganon, Filip Garbicz, Ruben Carrasco, John Hatcher, Andres Ramirez‐Gamero, Dominic Pizzarella, Amanda Kofides, Shirong Liu, Hao Sun, Xia Liu, María L. Guerrera, Andrew R. Branagan, Gottfried von Keudell, Shayna R. Sarosiek, Jorge J. Castillo, Zachary R. Hunter, Steven P. Treon   +18 more
wiley   +1 more source

Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry

Libraries of DNA-Encoded small molecules created using combinatorial chemistry and synthetic oligonucleotides are being applied to drug discovery projects across the pharmaceutical industry.
Maskos, Klaus, Thomson, Heather A., Bergmann, Andreas, Cuozzo, John W., Makino, Debora L. Konz, Augustin, Martin, Tian, Xia, Daether, Maike, Clark, Matthew A., Lammens, Alfred, Liu, Yanbin, Mrosek, Michael, Keefe, Anthony . D., Pfluegler, Klaus, Kiefersauer, Reiner, Siegert, Markus, Archana, Archna, Habeshian, Sevan, Krapp, Stephan, Centrella, Paolo A., Liu, Julie, Lercher, Lukas, Guilinger, John P., Guie, Marie-Aude, Zhang, Ying   +24 more
core   +1 more source

Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations

Blood Cancer Journal
BTK inhibitors (BTKi) have become standard of care for treatment of patients with chronic lymphocytic leukemia (CLL). Covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib are effective but alterations in the kinase domain at C481 or ...
Natalia Timofeeva, Breana Herrera, Hitomi Fujiwara, Tokiko Asami, Hiroko Endo, Mariko Hatakeyama, Fumio Nakajima, Hiroshi Ohmoto, Yu Nishioka, Kyoko Miyamoto, Akinori Arimura, Shady I. Tantawy, Javier Pinilla-Ibarz, Catherine C. Coombs, Nitin Jain, Masaaki Sawa, Varsha Gandhi   +16 more
doaj   +1 more source

Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma

Medicine in Novel Technology and Devices
Exploring novel therapeutic targets of Diffuse large B cell lymphoma (DLBCL) to overcome its resistance to Bruton's Tyrosine Kinase (BTK) inhibitors is a key topic.
Zhuojun Liu, Chenyue Wu, Zhaohua Yao, Yuxuan Wang, Zhe Yu, Jian Yu   +5 more
doaj   +1 more source

Design, Synthesis And Characterization Of Novel Pirtobrutinib Analogues As Anticancer BTK Inhibitors

Bruton tyrosine kinase (BTK) is a validated therapeutic target in B-cell malignancies, and pirtobrutinib is an important non-covalent BTK inhibitor developed to retain activity in settings where resistance to covalent BTK inhibitors may occur.
Dr. Shilpa S. Kolhe, Dr. Nagnath R. Kadam, Dr. Ramesh D. Ingole, Dr. Rahulkumar D. Rahane, Milind B. Suryawanshi, Dr. Hemant A. Deokule, Laxman Prabhakar Musale, Ratnadip M. Tapare   +7 more
core   +1 more source

Three generations, one target: BTK inhibitors in lymphoma. [PDF]

Blood Adv
Schmitt A, Hailfinger S.
europepmc   +1 more source